Aurenar is a company developing a non-invasive, single-use neuromodulation platform to reduce life-threatening complications in ICU patients. The company's transauricular vagus nerve stimulation (taVNS) device targets the body's inflammatory response to improve outcomes, lower total cost of care, and transform critical care management. Beginning with the impacts of stroke, Aurenar's platform is positioned to expand to address multiple high-acuity indications.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
07/28/26	$5,700,000	Seed	American Heart Association Ventures BJC Health Kaleida Capital Solas Bioventures	undisclosed